Pharosyn raises $3m seed to speed pharmaceutical commercial decisions
The AI platform turns clinical, regulatory and market signals into source-traceable intelligence for pharmaceutical teams.
From market signals to working intelligence
Pharosyn’s platform monitors clinical and regulatory developments, deals, hiring, epidemiology and social media, then filters those signals against a pharmaceutical company’s asset strategy. Teams receive reports and alerts linked to source data, giving commercial and competitive-intelligence staff a way to move from a broad stream of activity to evidence they can assess.
The $3 million seed round will accelerate product development and commercial decisions for pharmaceutical companies. Pharosyn says a top-ten biopharma customer already uses the system, while its congress workflow can deliver coverage in minutes and produce editable summary decks for follow-up analysis.
Use of funds
Accelerate product development and commercial decisions for pharmaceutical companies